Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? - PubMed (original) (raw)
Review
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Manfredi Rizzo et al. Expert Opin Pharmacother. 2011 Mar.
Abstract
Introduction: Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.
Areas covered: The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.
Expert opinion: Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprotein (HDL) cholesterol concentrations. Additional effects on pro-atherogenic lipoproteins and apolipoproteins include those on remnant-like particles, HDL subclasses, apolipoprotein B and postprandial lipemia. Cilostazol can improve the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes. Further studies are needed to establish whether cilostazol treatment exerts clinically relevant effects on atherogenic dyslipidemia in high-risk patients.
Similar articles
- Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Wang T, et al. Atherosclerosis. 2003 Dec;171(2):337-42. doi: 10.1016/j.atherosclerosis.2003.08.017. Atherosclerosis. 2003. PMID: 14644405 Clinical Trial. - Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo.
Nakaya K, Ayaori M, Uto-Kondo H, Hisada T, Ogura M, Yakushiji E, Takiguchi S, Terao Y, Ozasa H, Sasaki M, Komatsu T, Ohsuzu F, Ikewaki K. Nakaya K, et al. Atherosclerosis. 2010 Nov;213(1):135-41. doi: 10.1016/j.atherosclerosis.2010.07.024. Epub 2010 Jul 27. Atherosclerosis. 2010. PMID: 20723893 - The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?
Rizzo M, Christ ER, Rini GB, Spinas GA, Berneis K. Rizzo M, et al. Expert Opin Pharmacother. 2008 Sep;9(13):2295-303. doi: 10.1517/14656566.9.13.2295. Expert Opin Pharmacother. 2008. PMID: 18710354 Review. - Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Pastromas S, et al. Int J Cardiol. 2008 May 7;126(1):3-12. doi: 10.1016/j.ijcard.2007.04.172. Epub 2007 Aug 8. Int J Cardiol. 2008. PMID: 17689745 Review.
Cited by
- Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.
Hong S, Lee WJ, Park CY. Hong S, et al. Endocrinol Metab (Seoul). 2022 Apr;37(2):233-242. doi: 10.3803/EnM.2021.1353. Epub 2022 Apr 6. Endocrinol Metab (Seoul). 2022. PMID: 35381686 Free PMC article. Clinical Trial. - Cilostazol for intermittent claudication.
Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Brown T, et al. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5. Cochrane Database Syst Rev. 2021. PMID: 34192807 Free PMC article. - Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects.
Kim JR, Jung JA, Kim S, Huh W, Ghim JL, Shin JG, Ko JW. Kim JR, et al. Biomed Res Int. 2019 Jan 9;2019:1365180. doi: 10.1155/2019/1365180. eCollection 2019. Biomed Res Int. 2019. PMID: 30729119 Free PMC article. - Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of north India.
Aiman U, Haseen MA, Beg MH, Khan RA, Siddiqui FA, Alam I. Aiman U, et al. Indian J Pharm Sci. 2014 Nov-Dec;76(6):504-9. Indian J Pharm Sci. 2014. PMID: 25593383 Free PMC article. - Cilostazol for intermittent claudication.
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358850 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical